Document is current
Any future updates will be listed below
-
Authors
Goel, Utkarsh
Charalampous, Charalampos
Kapoor, Prashant https://orcid.org/0000-0002-4342-364X
Binder, Moritz https://orcid.org/0000-0001-9014-9658
Buadi, Francis K. https://orcid.org/0000-0003-3214-0203
Dingli, David https://orcid.org/0000-0001-7477-3004
Dispenzieri, Angela https://orcid.org/0000-0001-8780-9512
Fonder, Amie
Gertz, Morie A. https://orcid.org/0000-0002-3853-5196
Gonsalves, Wilson I.
Hayman, Suzanne R.
Hobbs, Miriam A.
Hwa, Yi L.
Kourelis, Taxiarchis https://orcid.org/0000-0001-8573-9434
Lacy, Martha Q.
Leung, Nelson
Lin, Yi https://orcid.org/0000-0002-1556-6416
Warsame, Rahma M.
Kyle, Robert A.
Rajkumar, S. Vincent https://orcid.org/0000-0002-5862-1833
Kumar, Shaji K. https://orcid.org/0000-0001-5392-9284
- License Information
-
More Information
Article History
Received: 19 October 2022
Revised: 23 December 2022
Accepted: 5 January 2023
First Online: 11 January 2023
Competing interests
: PK: Sanofi, BMS, Abbvie (Honoraria and Research Funding), Regeneron, Amgen, Ichnos, Loxo, Karyopharma, Takeda (Research Funding), Casma, Pharamcyclics, Imedex, GSK, Cellectar, Oncopeptides, X4 Pharmaceuticals (Honoraria). DD: Alexion, Apellis, BMS, Novartis, Roche, Sanofi (Consultancy), Regeneron (Research Funding). AD: Alynlam, Pfizer, Takeda, BMS (Research Funding), Janssen (Membership on an entity’s Board of Directors or advisory committees), Oncopeptides, Sorrento (Data monitoring safety committee). MAG: Ionis/Akcea, Prothena, Sanofi, Janssen, Aptitude Healthgrants, Ashfield, Juno, Physicians Education Resource, Johnson & Johnson, Celgene, Research to Practice, Sorrento (Personal Fees), Abbvie (Membership on an entity’s Board of Directors or advisory committees and Data monitoring safety committee), i3Health (Development of educational materials), TK: Novartis (Research Funding), MQL: Celgene (Research Funding), NL: Takeda (Membership on an entity’s Board of Directors or advisory committees), YL: Bluebird Bio, Celgene, Janssen, Kite (Consultancy and Research Funding), Gamida Cell, Novartis, Juno, Legend, Sorrento, Vineti (Consultancy), Merck, Takeda (Research Funding), Abbvie, Celgene, Janssen, Takeda, Adaptive, MedImmune/Astra Zeneca (Membership on an entity’s Board of Directors or advisory committees), Kite, Merck, Novartis, Roche, Sanofi (Research Funding), Oncopeptides (Independent review committee). The remaining authors declare no competing interests.
